. The majority
of participants that did not respond to the treatment had received chemotherapy in the metastatic
castration-resistant prostate cancer (mCR P C) stage, were part of the lowest dose cohort (cohort 1)
and had some of the highest PSA levels at study entry.
Thats makes sense. They had the lowest dose but were already at the cancer stops responding to hormone treatment, and it is found in other parts of the body.
- Forums
- ASX - By Stock
- Ann: SECuRE trial update
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
6.70%
!
$2.23

. The majority of participants that did not respond to the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.23 |
Change
0.140(6.70%) |
Mkt cap ! $671.8M |
Open | High | Low | Value | Volume |
$2.09 | $2.24 | $2.07 | $2.878M | 1.315M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 6905 | $2.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.23 | 3053 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 10898 | 2.220 |
12 | 26579 | 2.210 |
11 | 33324 | 2.200 |
9 | 24999 | 2.190 |
5 | 10059 | 2.180 |
Price($) | Vol. | No. |
---|---|---|
2.240 | 16820 | 10 |
2.250 | 75468 | 14 |
2.260 | 18244 | 9 |
2.270 | 10451 | 6 |
2.280 | 9000 | 1 |
Last trade - 10.32am 26/06/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online